Keywords: Cervical cancer vaccines, Cost bnefit, Merck & Co, Gardasil, GlaxoSmithKline, Cervarix, UK, Health Protection Agency

Cost benefit analysis of cervical cancer vaccines sees Gardasil beat Cervarix

Article | 29 September 2011

Print This

An analysis of cervical-cancer vaccine has shown that Merck & Co’s (NYSE: MRK) Gardasil (human papillomavirus quadrivalent [types 6, 11, 16 ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in